ADAR1 Capital Management LLC bought a new position in shares of Danaher Corporation (NYSE:DHR - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 25,932 shares of the conglomerate's stock, valued at approximately $4,940,000.
Other large investors have also recently made changes to their positions in the company. EP Wealth Advisors LLC bought a new stake in shares of Danaher in the second quarter valued at about $3,807,000. Northwestern Mutual Wealth Management Co. grew its holdings in Danaher by 303.7% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 248,020 shares of the conglomerate's stock worth $56,777,000 after acquiring an additional 186,584 shares in the last quarter. Puzo Michael J bought a new position in Danaher during the 2nd quarter worth about $8,624,000. Legal & General Group Plc increased its position in Danaher by 1.0% during the 4th quarter. Legal & General Group Plc now owns 4,495,287 shares of the conglomerate's stock valued at $1,029,061,000 after purchasing an additional 43,169 shares during the period. Finally, Madison Asset Management LLC purchased a new position in Danaher during the 2nd quarter valued at about $85,451,000. 79.05% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
DHR has been the subject of several research reports. Evercore reaffirmed an "outperform" rating and issued a $230.00 price target on shares of Danaher in a research report on Monday, July 6th. TD Cowen cut their price objective on shares of Danaher from $240.00 to $236.00 and set a "buy" rating on the stock in a report on Wednesday, July 22nd. Stifel Nicolaus reduced their price objective on shares of Danaher from $260.00 to $220.00 and set a "buy" rating for the company in a research note on Wednesday, July 22nd. HSBC lowered their target price on Danaher from $270.00 to $230.00 and set a "buy" rating for the company in a report on Wednesday, June 3rd. Finally, Wolfe Research cut Danaher from an "outperform" rating to a "peer perform" rating in a research report on Monday, June 1st. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Danaher currently has an average rating of "Moderate Buy" and an average target price of $228.91.
Read Our Latest Stock Analysis on DHR
Danaher Stock Performance
DHR stock opened at $215.78 on Wednesday. The firm has a market cap of $151.69 billion, a price-to-earnings ratio of 38.33, a PEG ratio of 2.68 and a beta of 0.78. The firm has a 50-day simple moving average of $197.17 and a two-hundred day simple moving average of $192.36. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65.
Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating analysts' consensus estimates of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business had revenue of $6.26 billion for the quarter, compared to analysts' expectations of $6.12 billion. During the same period last year, the business earned $0.77 EPS. The company's revenue was up 5.5% compared to the same quarter last year. On average, equities analysts forecast that Danaher Corporation will post 8.53 EPS for the current fiscal year.
About Danaher
(
Free Report)
Danaher Corporation NYSE: DHR is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.
Products and services in Danaher's portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.
Featured Stories
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
